-+ 0.00%
-+ 0.00%
-+ 0.00%
HUTCHMED Receives China National Medical Products Administration Simultaneous Approval For Two New Drug Applications For Syvik Oral Small Molecule Inhibitor Targeting Spleen Tyrosine Kinase
Share
Listen to the news

Immune Thrombocytopenia ("ITP"): For the treatment of adult patients with chronic primary ITP who have had an insufficient response to at least one prior therapy; and
Warm Antibody Autoimmune Hemolytic Anemia ("wAIHA"): For the treatment of adult patients with wAIHA who who have had an insufficient response to prior corticosteroid therapy.


The approval for ITP is supported by data from ESLIM-01 (NCT05029635), a randomized, double-blinded, placebo-controlled Phase III trial in China of SYVIK® in 188 adult patients who had received at least one prior line of standard therapy. Results from ESLIM-01 study were published in The Lancet Haematology. SYVIK® demonstrated a clinically meaningful early and sustained durable platelet response in patients with primary ITP compared to placebo, with durable response rate of 48.4% compared to zero with placebo (p<0.0001). Overall response rates were 68.3% at 0–12 weeks and 70.6% at 0–24 weeks with SYVIK®, compared to 14.5% and 16.1% with placebo (p<0.0001). SYVIK® demonstrated a tolerable safety profile and improvement in quality of life.

The approval for wAIHA is supported by data from ESLIM-02 (NCT05535933), a randomized, double-blind, placebo-controlled Phase II/III study in adult patients with primary or secondary wAIHA who had relapsed or were refractory to prior glucocorticoid treatment. Results from the Phase II part of ESLIM-02 were published in The Lancet Haematology. Results from the Phase III part were presented at the European Hematology Association ("EHA") 2026 Congress. SYVIK® demonstrated a significantly higher durable response rate during weeks 5–24 compared to placebo (66% vs 15%, p<0.0001). During the 24-week double-blind treatment period, SYVIK® demonstrated superior efficacy across several key metrics; specifically, the overall response rate — defined as hemoglobin ≥100 g/L with an increase of ≥20 g/L from baseline without rescue therapy — was significantly increased (70% vs 22%, p<0.0001). SYVIK® demonstrated a favorable safety profile with no treatment-related deaths or discontinuations in the SYVIK® group.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending